株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

筋ジストロフィー:パイプライン製品の分析

Muscular Dystrophy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 227546
出版日 ページ情報 英文 144 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
筋ジストロフィー:パイプライン製品の分析 Muscular Dystrophy - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 144 Pages
概要

筋ジストロフィーは、遺伝性疾患のグループに入り、筋肉組織がダメージを受けやすくなって損傷した筋肉が弱くなっていく進行性の疾患です。症状は通常6歳より前に表れ、幼児期の早い段階に発生します。疲労感や学習障害、知的障害、筋力低下、進行性の歩行困難を伴います。

当レポートでは、筋ジストロフィーの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

筋ジストロフィーの概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

筋ジストロフィー:企業で開発中の治療薬

筋ジストロフィー:大学/機関で研究中の治療薬

筋ジストロフィー:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

筋ジストロフィー:企業で開発中の製品

筋ジストロフィー:大学/機関で研究中の製品

筋ジストロフィーの治療薬開発に従事している企業

  • Acceleron Pharma, Inc.
  • AMO Pharma Limited
  • 旭化成ファーマ
  • aTyr Pharma, Inc.
  • Benitec Biopharma Limited
  • Bioblast Pharma Ltd.
  • BioMarin Pharmaceutical Inc.
  • Biophytis SAS
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Fate Therapeutics, Inc.
  • Genethon
  • Ionis Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • Novogen Limited
  • Prothelia, Inc.
  • SanBio, Inc.
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics, Inc.
  • Selecta Biosciences, Inc.
  • 武田薬品工業
  • WAVE Life Sciences Ltd.

筋ジストロフィー:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

筋ジストロフィー:最近のパイプライン動向

筋ジストロフィー:休止中のプロジェクト

筋ジストロフィー:開発が中止された製品

筋ジストロフィー:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8655IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H2 2016, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 24 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 4 molecules, respectively.Muscular Dystrophy.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Muscular Dystrophy Overview
  • Therapeutics Development
    • Pipeline Products for Muscular Dystrophy - Overview
    • Pipeline Products for Muscular Dystrophy - Comparative Analysis
  • Muscular Dystrophy - Therapeutics under Development by Companies
  • Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes
  • Muscular Dystrophy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Muscular Dystrophy - Products under Development by Companies
  • Muscular Dystrophy - Products under Investigation by Universities/Institutes
  • Muscular Dystrophy - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • AMO Pharma Limited
    • Asahi Kasei Pharma Corp.
    • aTyr Pharma, Inc.
    • Benitec Biopharma Limited
    • Bio Blast Pharma Ltd.
    • Biophytis SAS
    • Corcept Therapeutics Incorporated
    • Evotec AG
    • F. Hoffmann-La Roche Ltd.
    • Genethon
    • Ionis Pharmaceuticals, Inc.
    • Marina Biotech, Inc.
    • Medestea Research & Production S.p.A.
    • Novogen Limited
    • Pfizer Inc.
    • Prothelia, Inc.
    • SanBio, Inc.
    • Santhera Pharmaceuticals Holding AG
    • Sarepta Therapeutics, Inc.
    • Selecta Biosciences, Inc.
    • Strykagen Corporation
    • Takeda Pharmaceutical Company Limited
    • WAVE Life Sciences Ltd.
  • Muscular Dystrophy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACE-083 - Drug Profile
    • Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile
    • Antisense RNAi Oligonucleotides for Myotonic Dystrophy - Drug Profile
    • ATYR-1940 - Drug Profile
    • baliforsen - Drug Profile
    • BIO-103 - Drug Profile
    • domagrozumab - Drug Profile
    • Drugs for Merosin-Deficient Congenital Muscular Dystrophy Type 1A - Drug Profile
    • elcatonin - Drug Profile
    • Gene Therapy for Muscular Dystrophy and Liver Diseases - Drug Profile
    • Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile
    • Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile
    • Gene Therapy to Activate Dystrophin for Muscular Dystrophy - Drug Profile
    • IUCT-169 - Drug Profile
    • IUCT-290 - Drug Profile
    • IUCT-309 - Drug Profile
    • ketoprofen - Drug Profile
    • LR-08 - Drug Profile
    • MED-1101 - Drug Profile
    • mexiletine hydrochloride - Drug Profile
    • Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy - Drug Profile
    • Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile
    • omigapil - Drug Profile
    • Pabparna - Drug Profile
    • poloxamer - Drug Profile
    • PRT-01 - Drug Profile
    • Recombinant Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile
    • RNAi Gene Therapy to Inhibit Myotilin for LGMD - Drug Profile
    • RP-33 - Drug Profile
    • SB-308 - Drug Profile
    • SIWA-318 - Drug Profile
    • Small Molecule to Inhibit DUX4 for Muscular Dystrophy - Drug Profile
    • Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile
    • Small Molecule to Target RNA for Myotonic Dystrophy - Drug Profile
    • Small Molecules for Dysferlinopathies - Drug Profile
    • Small Molecules for Facioscapulohumeral Muscular Dystrophy - Drug Profile
    • Small Molecules for Myotonic Dystrophy - Drug Profile
    • Small Molecules for Myotonic Dystrophy Type 1 - Drug Profile
    • Small Molecules to Activate SMCHD1 for Facioscapulohumeral Dystrophy - Drug Profile
    • Small Molecules to Antagonize Glucocorticoid Receptor II for Muscular Dystrophy - Drug Profile
    • Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I - Drug Profile
    • Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile
    • SRT-149 - Drug Profile
    • SRT-152 - Drug Profile
    • Stem Cell Therapy for Muscular Dystrophy - Drug Profile
    • Stryka-232 - Drug Profile
    • Stryka-234 - Drug Profile
    • Stryka-425 - Drug Profile
    • Stryka-533 - Drug Profile
    • Stryka-978 - Drug Profile
    • tideglusib - Drug Profile
    • trehalose - Drug Profile
    • TXA-127 - Drug Profile
    • VAL-0411 - Drug Profile
    • VAL-1205 - Drug Profile
  • Muscular Dystrophy - Dormant Projects
  • Muscular Dystrophy - Discontinued Products
  • Muscular Dystrophy - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Muscular Dystrophy, H2 2016
  • Number of Products under Development for Muscular Dystrophy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by AMO Pharma Limited, H2 2016
  • Muscular Dystrophy - Pipeline by Asahi Kasei Pharma Corp., H2 2016
  • Muscular Dystrophy - Pipeline by aTyr Pharma, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by Benitec Biopharma Limited, H2 2016
  • Muscular Dystrophy - Pipeline by Bio Blast Pharma Ltd., H2 2016
  • Muscular Dystrophy - Pipeline by Biophytis SAS, H2 2016
  • Muscular Dystrophy - Pipeline by Corcept Therapeutics Incorporated, H2 2016
  • Muscular Dystrophy - Pipeline by Evotec AG, H2 2016
  • Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Muscular Dystrophy - Pipeline by Genethon, H2 2016
  • Muscular Dystrophy - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Muscular Dystrophy - Pipeline by Novogen Limited, H2 2016
  • Muscular Dystrophy - Pipeline by Pfizer Inc., H2 2016
  • Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by SanBio, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016
  • Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by Selecta Biosciences, Inc., H2 2016
  • Muscular Dystrophy - Pipeline by Strykagen Corporation, H2 2016
  • Muscular Dystrophy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Muscular Dystrophy - Dormant Projects, H2 2016
  • Muscular Dystrophy - Dormant Projects (Contd..1), H2 2016
  • Muscular Dystrophy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Muscular Dystrophy, H2 2016
  • Number of Products under Development for Muscular Dystrophy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top